Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone

Neuroendocrinology Letters

Volumn 33, Issue 2, 2012, Pages 236-244

  Barteček, Richard ^a,b   Juřica, Jan ^a   Zrůstová, Jana ^b   Kašpárek, Tomáš ^a,b   Pindurová, Eva ^b   Žourková, Alexandra ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

CYP2D6; CYP2D6 analysis; Cytochrome P 450; Pharmacogenetics; Risperidone; Schizophrenia

Indexed keywords

AMANTADINE; BIPERIDEN; CHLORPROTHIXENE; CLONAZEPAM; CYTOCHROME P450 2D6; DIAZEPAM; HALOPERIDOL; LEVOCETIRIZINE; LEVOMEPROMAZINE; METOPROLOL; OLANZAPINE; OXAZEPAM; PALIPERIDONE; PROMETHAZINE; RAMIPRIL; RISPERIDONE; ZOLPIDEM; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CYPD 2D6 GENE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEART PALPITATION; HUMAN; MALE; NAUSEA; ORTHOSTATIC DIZZINESS; POLYDIPSIA; POLYURIA; PROSPECTIVE STUDY; SALIVATION; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SIDE EFFECT; SWEATING; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME; VOMITING;

EID: 84862273919     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Albrecht A, Morena PG, Baumann P, Eap CB, (2004). High dose of depot risperidone in a nonresponder schizophrenic patient. J Clin Psychopharmacol 24: 673-674.
2. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449.
3. Aravagiri, M, Marder SR, Nuechterlein KH, Gitlin MJ, (2003). Intra-and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit 25: 657-664.
4. Arranz MJ, de Leon J (2007). Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12: 707-747.
5. Berecz R, LLerena A, de la Rubia A, Gomez J, Kellermann M, Dorado P, et al (2002). Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and cyp2d6 enzyme activity in psychiatric patients. Pharmacopsychiatry 35: 231-234.
6. Bork JA, Rogers T, Wedlund PJ, de Leon J (1999). A pilot study on risperidone metabolism: the role of cytochromes p450 2d6 and 3a. J Clin Psychiatry 60: 469-476.
7. Daly AK, Steward A (1995). Use of the expand long template pcr system in genotyping for polymorphisms in the human cytochrome p450 cyp2d6 gene. Biochemica 4: 31-32.
8. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ, et al (2005). The cyp2d6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
9. de Leon J, Wynn G, Sandson NB (2010). The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51: 80-88.
10. Dutheil F, Beaune P, Loriot MA (2008). Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome p450 enzymes in normal and pathological human brain. Biochimie 90: 426-436.
11. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome p450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 14: 1-157.
12. Human Cytochrome P450 Allele Nomenclature Committee (2011). CYP2D6 allele nomenclature. http://www.cypalleles.ki.se/cyp2d6.htm.
13. Ingelman-Sundberg M (2005). Genetic polymorphisms of cytochrome p450 2d6 (cyp2d6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5: 6-13.
14. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM (2010). The role of cyp2d6 and abcb1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66: 1109-1117.
15. Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, et al (2005). Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome p450 2d6. Int Clin Psychopharmacol 20: 71-78.
16. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-ht2 and d2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
17. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull 13: 261-276.
18. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9: 442-473.
19. Koehnke MD, Griese EU, Stoesser D, Gaertner I, Barth G (2002). Cytochrome p450 2d6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35: 116-118.
20. Laika B, Leucht S, Heres S, Steimer W (2009). Intermediate metabolizer: increased side effects in psychoactive drug therapy. the key to cost-effectiveness of pretreatment cyp2d6 screening? Pharmacogenomics J 9: 395-403.
21. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K (1987). The uku side effect rating scale, a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1-100.
22. Llerena A, Berecz R, Dorado P, de la Rubia A (2004). Qtc interval, cyp2d6 and cyp2c9 genotypes and risperidone plasma concentrations. J Psychopharmacol 18: 189-193.
23. NIMH Psychoactive Drug Screening Program (2011). Pdsp - home page. http://pdsp.med.unc.edu/.
24. Nord M, Farde L (2011). Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17: 97-103.
25. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K (1998). Serum concentrations and side effects in psychiatric patients during risperidone therapy.Ther Drug Monit 20: 380-384.
26. Plesnicar BK, Zalar B, Breskvar K, Dolzan V (2006). The influence of the cyp2d6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 20: 829-833.
27. R Development Core Team (2011). R: a language and environment for statistical computing. http://www.r-project.org/.
28. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Mueller-Arends A, Weber K, et al (2005). Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255: 261-268.
29. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L (2001). Risperidone metabolism in relation to cyp2d6*10 allele in korean schizophrenic patients. Eur J Clin Pharmacol 57: 671-675.
30. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML (1999). Cytochrome p450 2d6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147: 300-305.
31. Sistonen J, Fuselli S, Levo A, Sajantila A, (2005). Cyp2d6 genotyping by a multiplex primer extension reaction. Clin Chem 51: 1291-1295.
32. Svensson TH (2003). Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1145-1158.
33. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, et al. (1998). 5-ht2a receptor blockade in patients with schizophrenia treated with risperidone or clozapine. a spet study using the novel 5-ht2a ligand 123i-5-i-r-91150. Br J Psychiatry 173: 236-241.
34. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, et al. (2007). Prolactin release in children treated with risperidone: impact and role of cyp2d6 metabolism. J Clin Psychopharmacol 27: 52-57.
35. Zhang JP, Malhotra AK (2011). Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7: 9-37.